In Brief: Intelligent Medical Imaging/Coulter
This article was originally published in The Gray Sheet
Intelligent Medical Imaging/Coulter: Sign agreement March 27 to terminate Coulter's exclusive sales and distribution agreement for IMI's MICRO21 automated microscope system. IMI will pay Coulter $4.2 mil. to end an arbitration proceeding initiated by IMI. IMI says the settlement "will be reflected as a one-time non-recurring charge" of $2.3 mil. in its 1996 financial statements. IMI will now market the microscope system through its 23 sales reps and distributors...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.